Dec. 25, 2025 (Thursday) is Christmas Day in the U.S. — and that matters because there was no regular trading session and no closing bell today. U.S. stock markets were closed for the holiday, with the last regular session ending early on Wednesday, Dec. 24.
So if you’re checking AbbVie Inc. (NYSE: ABBV) “after the bell” on Dec. 25, what you’re really looking at is the latest available post-close/extended-hours pricing from Dec. 24, plus any fresh news/analysis published today that could influence sentiment when the market reopens Friday, Dec. 26, 2025. Reuters
ABBV’s latest price: last close (Dec. 24) and extended-hours snapshot
Because the market closed early on Dec. 24, AbbVie’s most recent official close came from that shortened session:
- Last close (Dec. 24): $229.89, up $1.10 (+0.48%)
- Day range (Dec. 24): $228.98 to $230.80
- Volume (Dec. 24): ~1.74 million shares
In extended-hours indications reported after that close, ABBV was little changed:
- After-hours: $229.85 (−$0.04 / −0.02%) with after-hours volume ~342K (delayed quote)
Takeaway: heading into Friday’s reopen, ABBV is effectively starting from a flat-to-slightly-soft after-hours tape, with the bigger driver likely to be broader market tone and any fresh healthcare/pharma headlines that emerge into the reopening session.
Why there was no “after the bell” move on Dec. 25
U.S. equities were closed Thursday, Dec. 25 (Christmas Day), following the standard holiday schedule.
Also relevant: the prior session (Dec. 24) ended early — a structure that typically creates lighter liquidity and more “headline-sensitive” price action once normal trading resumes. Reuters
The most important market-context headline today: Dec. 26 and the “Santa Claus rally” effect
A notable piece circulating today is the seasonal-market setup around Dec. 26. Historically, market researchers have pointed out that Dec. 26 has often been among the more consistently positive days of the year for the S&P 500, though strategists repeatedly caution that seasonality is not a trading system and can fail—especially in thin holiday markets.
For ABBV specifically, this matters because large-cap defensives and dividend names can sometimes benefit when the tape is calm and risk appetite is supportive—while thin liquidity can amplify moves if macro or political headlines surprise investors.
“Today’s” ABBV headlines: what actually crossed the wires on Dec. 25
1) No new AbbVie press releases today
AbbVie’s own newsroom shows the most recent company-posted items earlier in December, not on Dec. 25.
That doesn’t mean nothing is happening—only that there wasn’t a fresh company announcement today that would typically reprice the stock overnight.
2) Institutional-ownership updates and filings surfaced today (secondary, but watchable)
Several finance sites published Dec. 25 write-ups tied to institutional position disclosures (largely reflecting prior-quarter filings rather than “today’s buying” in real time). These pieces are rarely primary catalysts on their own, but they can influence retail attention and sentiment around “who’s buying.” MarketBeat
3) A valuation-style deep dive was published today
A Simply Wall St analysis published today argues ABBV may screen as undervalued under a discounted cash flow (DCF) framework, presenting a notably higher “intrinsic value” estimate than the current market price. Treat this as one model, highly assumption-driven, rather than a consensus forecast. Simply Wall St
The fundamental backdrop investors are still trading: what’s been driving ABBV into year-end
To understand what could matter most when the market reopens, it helps to anchor on the company fundamentals investors have been reacting to in recent months:
AbbVie’s 2025 operating narrative: replacing Humira, scaling Skyrizi and Rinvoq
In its Q3 2025 update, AbbVie reported:
- Net revenues: $15.776B (+9.1% year over year)
- Immunology portfolio: $7.885B
- Skyrizi: $4.708B
- Rinvoq: $2.184B
- Humira: $993M (declining sharply year over year)
Guidance and dividend support remain central to the bull case
AbbVie also raised its 2025 adjusted diluted EPS guidance to $10.61–$10.65 and announced a 5.5% dividend increase, lifting the quarterly dividend from $1.64 to $1.73, starting with the payment scheduled for Feb. 17, 2026 (record date Jan. 16, 2026).
For many investors, that combination—guidance confidence + dividend growth—is the “core” support under ABBV when the market gets choppy.
Analyst forecast check: what Wall Street is pricing in for ABBV
A widely followed analyst-consensus snapshot (18 analysts) currently shows:
- Consensus rating: “Buy”
- Average 12-month price target: $242.28 (about +5% versus the latest price area)
- Target range: $190 (low) to $289 (high)
Important nuance for tomorrow’s open: price targets rarely move on a holiday. What can move quickly is risk sentiment, rates, and policy headlines that alter how investors discount future pharma cash flows.
Valuation debate: why different models disagree so much on ABBV
If you’re seeing conflicting “fair value” numbers today, you’re not imagining it.
- One DCF-oriented view published today suggests ABBV could be meaningfully undervalued if future cash flows expand as modeled.
- Another valuation service flags the opposite—suggesting ABBV could be modestly overvalued versus its own base-case intrinsic estimate.
This spread is typical for mature pharma: small differences in assumptions around drug durability, competition, pipeline success, and pricing policy can swing valuation dramatically.
Technical and positioning context: key levels into Friday, Dec. 26
From widely reported market data:
- 52-week high: $244.81 (Oct. 1, 2025)
- 52-week low: $164.39 (Apr. 9, 2025)
- ABBV is up ~34% year-to-date and up ~28% over the last 12 months (figures vary slightly by data vendor).
What that suggests for the open:
- ABBV is not coming into Friday “washed out.” It’s coming in as a strong 2025 performer, which can cut both ways:
- supportive if markets lean risk-on,
- vulnerable if year-end profit-taking shows up in crowded winners.
Macro check before the open: the data backdrop investors just got
One macro input worth noting into Friday is the most recent U.S. labor-market read:
- Initial jobless claims: 214,000 for the week ending Dec. 20 (down 10,000 from the prior week).
While ABBV isn’t a “jobs-driven” stock day to day, macro data influences rates and the overall risk bid, which can spill into large-cap healthcare.
A policy risk that can still swing big pharma sentiment fast
Even without a fresh AbbVie-specific release today, broader pharma policy remains a live wire. Reuters reported recently that AbbVie and other drugmakers have been involved in discussions tied to U.S. drug-pricing initiatives (including most-favored-nation style frameworks), developments that can re-enter the tape quickly and affect sector multiples.
What to know before the market opens tomorrow (Friday, Dec. 26, 2025)
Here’s the practical checklist for ABBV watchers heading into the reopen:
- Know the schedule reality
- Markets were closed Dec. 25.
- Dec. 26 is a full trading day for major U.S. exchanges.
- Expect thinner liquidity than normal
- The market is coming off an early close and a full holiday shutdown, which can mean wider spreads and faster swings on headlines.
- Watch broad-market tone first, ABBV second
- ABBV’s after-hours move is minimal; the bigger determinant may be whether the market leans into the seasonal “Santa Claus rally” narrative or fades it. MarketWatch
- Monitor healthcare/pharma policy headlines
- Any renewed reporting on U.S. drug pricing frameworks can move the group quickly, including ABBV.
- Keep ABBV’s story straight
- Investors remain focused on Skyrizi/Rinvoq growth, the Humira erosion path, and shareholder returns via guidance and dividends.
Bottom line
On Dec. 25, 2025, AbbVie stock didn’t trade because U.S. markets were closed. The latest actionable price reference remains Dec. 24’s $229.89 close, with after-hours indications near $229.85–$229.90.
For Friday, Dec. 26, the highest-probability drivers are: holiday liquidity, overall market direction, and any fresh pharma-policy headlines, while ABBV’s longer-running narrative stays anchored to its immunology growth engines and dividend story.
This article is for informational purposes only and is not investment advice.
